Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1999 1
2000 1
2002 62
2003 92
2004 57
2005 48
2006 82
2007 96
2008 81
2009 109
2010 110
2011 104
2012 98
2013 131
2014 109
2015 127
2016 110
2017 117
2018 112
2019 93
2020 93
2021 116
2022 80
2023 81
2024 91
2025 50

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,948 results

Results by year

Filters applied: . Clear all
Page 1
Management of chronic myeloid leukemia in 2025.
Kantarjian H, Breccia M, Haddad FG, Hehlmann R, Issa GC, Malhotra H, Nicolini FE, Sasaki K, Stenke L, Jabbour E. Kantarjian H, et al. Cancer. 2025 Jul 15;131(14):e35953. doi: 10.1002/cncr.35953. Cancer. 2025. PMID: 40616814 Review.
PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes.
Bazinet A, Bataller A, Montalban-Bravo G, Chien K, Sasaki K, Jen WY, Swaminathan M, Kadia T, DiNardo C, Ravandi F, Garcia-Manero G, Kantarjian H. Bazinet A, et al. Among authors: kantarjian h. Haematologica. 2025 Jul 3. doi: 10.3324/haematol.2025.287874. Online ahead of print. Haematologica. 2025. PMID: 40605709 Free article.
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation.
Uryu H, Saeki K, Haeno H, Kapadia CD, Furudate K, Nangalia J, Spencer Chapman M, Zhao L, Hsu JI, Zhao C, Chen S, Tanaka T, Li Z, Ogata S, Hanache S, Yang H, DiNardo C, Daver N, Pemmaraju N, Jain N, Ravandi F, Zhang J, Song X, Thompson E, Tang H, Little L, Gumbs C, Orlowski RZ, Qazilbash M, Bhalla K, Colla S, Kantarjian H, Kanagal-Shamanna R, Bueso-Ramos C, Nakada D, Al-Atrash G, Molldrem J, Futreal PA, Shpall E, Goodell M, Garcia-Manero G, Takahashi K. Uryu H, et al. Among authors: kantarjian h. Nat Genet. 2025 Jul 1. doi: 10.1038/s41588-025-02235-w. Online ahead of print. Nat Genet. 2025. PMID: 40596442
Managing BPDCN in the context of severe hyperbilirubinemia: a case study.
Croden J, Pemmaraju N, Fliehler K, Brown A, Wang W, Kantarjian H, Vega F, Kadia T. Croden J, et al. Among authors: kantarjian h. Leuk Lymphoma. 2025 Jun 26:1-4. doi: 10.1080/10428194.2025.2521653. Online ahead of print. Leuk Lymphoma. 2025. PMID: 40569706 No abstract available.
Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell / myeloid mixed phenotype acute leukemia.
Azevedo RS, Jen WY, Hammond D, Haddad FG, Geppner A, Issa GC, Sasaki K, Senapati J, Jabbour E, Ravandi F, Kantarjian H, Kadia TM. Azevedo RS, et al. Among authors: kantarjian h. Haematologica. 2025 Jun 26. doi: 10.3324/haematol.2025.287932. Online ahead of print. Haematologica. 2025. PMID: 40568715 Free article.
Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes.
Csizmar CM, Natu A, Gurney M, Fathima S, Alsugair AKA, Kanagal-Shamanna R, Loghavi S, Bazinet A, Chien K, Hammond D, DiNardo C, Kadia T, Ravandi-Kashani F, Pemmaraju N, Sasaki K, Lasho TL, Finke CM, Al-Kali A, Alkhateeb H, Begna K, Gangat N, Hefazi Torghabeh M, Matin A, Mangaonkar AA, Saliba AN, Tefferi A, Garcia-Manero G, Kantarjian HM, Komrokji RS, Xie Z, Ali NA, Sallman D, Padron E, Montalban-Bravo G, Patnaik MM. Csizmar CM, et al. Among authors: kantarjian hm. Leukemia. 2025 Jun 24. doi: 10.1038/s41375-025-02648-w. Online ahead of print. Leukemia. 2025. PMID: 40555734 No abstract available.
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial.
Jabbour E, Lussana F, Martínez-Sánchez P, Torrent A, Rifón JJ, Agrawal V, Tormo M, Cassaday RD, Cluzeau T, Huguet F, Papayannidis C, Hernández-Rivas JM, Rijneveld A, Fleming S, Vucinic V, Böll B, Ikezoe T, Abdul-Hay M, Savoie ML, Schuh AC, Berthon C, Schwartz S, Chiaretti S, Yuda J, Miyazaki T, González-Campos J, Chen Y, Wong H, Choudhry J, Zugmaier G, Guest E, Gordon P, Kantarjian H. Jabbour E, et al. Among authors: kantarjian h. Lancet Haematol. 2025 Jul;12(7):e529-e541. doi: 10.1016/S2352-3026(25)00144-9. Epub 2025 Jun 15. Lancet Haematol. 2025. PMID: 40532723 Clinical Trial.
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.
DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, Issa GC, Jen WY, Daver NG, Reville PK, Short NJ, Sasaki K, Mullin JK, Bradley CA, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Abbas HA, Hammond DE, Haddad F, Bravo GM, Chien KS, Yilmaz M, Kornblau SM, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Konopleva MY, Kantarjian HM. DiNardo CD, et al. Among authors: kantarjian hm. J Clin Oncol. 2025 Jun 13:JCO2500640. doi: 10.1200/JCO-25-00640. Online ahead of print. J Clin Oncol. 2025. PMID: 40513054
A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia.
Kadia TM, Jen WY, Bataller A, Bazinet A, Borthakur G, Jabbour E, Qiao W, Short NJ, Takahashi K, Issa GC, DiNardo CD, Montalban-Bravo G, Pemmaraju N, Tran A, Bharathi V, Loghavi S, Alousi AM, Popat U, Daver NG, Ravandi F, Kantarjian HM. Kadia TM, et al. Among authors: kantarjian hm. Am J Hematol. 2025 Aug;100(8):1365-1373. doi: 10.1002/ajh.27723. Epub 2025 May 22. Am J Hematol. 2025. PMID: 40401707 Clinical Trial.
1,948 results